Telomerase reverse transcriptase genetic modification of bone marrow mesenchymal stem cells in diabetes treatment
10.3969/j.issn.2095-4344.2015.28.022
- VernacularTitle:人端粒酶反转录酶基因修饰骨髓间充质干细胞静脉移植治疗糖尿病
- Author:
Jia LIU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2015;(28):4549-4554
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Pancreas or islet cel transplantation and stem cel transplantation bring hope to cure diabetes, but pancreas or islet transplantation appears to have a lack of donors as wel as immune rejection problems, limiting their clinical development. Therefore, stem cel transplantation therapy has become the current hotspot.
OBJECTIVE:To study the therapeutic effects of huaman telomerase reverse transcriptase (hTERT)-modified bone marrow mesenchymal stem cel s transplantation on diabetes mel itus in SD rats.
METHODS:Bone marrow mesenchymal stem cel s were transfected with PLXSN carrying hTERT. Thirty-six male SD rats were randomly divided into control group (n=6), stem cel group (n=10), hTERT transfection group (n=10), diabetes mel itus group (n=10). Except the control group, the rats were injected with stretozotocin (45 mg/kg) to make diabetes mel itus models. After modeling, rats in the stem cel group and hTERT transfection group were respectively intravenously injected with 1 mL of bone marrow mesenchymal stem cel s (1.5×1010/L) and 1 mL of hTERT-modified bone marrow mesenchymal stem cel s (1.5×1010/L).
RESULTS AND CONCLUSION:At 24 hours after modeling, the fasting blood-glucose level was significantly increased in the diabetes mel itus group, which was higher than the normal value (6.7 mmol/L). At 15 days after cel transplantation, the fasting blood-glucose levels were signficiantly decreased in the stem cel group and hTERT transfection group as compared with the diabetes mel itus group (P<0.05), but the body mass of rats was increased in these two group (P<0.05), especial y in the hTERT transfection group. At 45 days after cel transplantation, the fasting blood-glucose level and body mass in the stem cel group and hTERT transfection group were close to those in the control group (P>0.05), and moreover, the hTERT group had better outcomes than the stem cel group. Meanwhile, in the diabetes mel itus group, the fasting blood-glucose level was stil at a higher level, and the body mass decreased continously. These findings suggest that hTERT-modified bone marrow mesenchymal stem cel transplantation is effective for treatment of diabetes mel itus in rats.
